Zecotek Closes Second Tranche of Non-Brokered Private Placement Raises Aggregate Proceeds of $1.9 Million
Singapore, December 3, 2012 – Zecotek Photonics Inc. (TSX-V: ZMS; Frankfurt: W1I), a developer of leading-edge photonics technologies for medical, industrial and scientific markets, today announced that the Company has closed on the second tranche of the non-brokered private placement announced on September 18, 2012. The Company sold 944,444 units of the Company at a price of $0.36 per unit gross proceeds of $340,000. Together with the first tranche which closed on October 12, 2012, Zecotek has raised aggregate proceeds of $1,880,800.
Each unit consists of one common share and one-half of one common share purchase warrant. Each whole warrant entitles the holder to acquire one common share at an exercise price of $0.50 per common share at any time on or before the 24-month anniversary of the closing of the offering. The Warrant’s exercise period will automatically accelerate if the common shares of the Company trade above $1.00 for a period of 10 consecutive trading days.
Net proceeds from the funds raised will be used to pursue licensing agreements and technology transfer for commercialization, to build and maintain patents of the IP portfolio and for general working capital purposes.
Pursuant to the second tranche of the financing, the Company paid finder’s fees of $16,800 and issued 46,666 non-transferable finder’s warrants. For the total non-brokered private placement the Company paid total cash finders’ fees of $124,656 and issued 346,266 non-transferable finder’s warrants. Each finder’s warrant entitles the holder to purchase one common share at $0.50 for a period of 24 months after the date the private placement closes.
All securities issued under the second tranche are subject to a four-month hold period expiring on April 4, 2013. All securities issued under the first tranche which closed on October 12, 2012 are subject to a four-month hold period expiring on February 11, 2013.
– 30 –
Zecotek Photonics Inc (TSX-V: ZMS; Frankfurt: W1I) is a photonics technology company developing high-performance scintillation crystals, photo detectors, positron emission tomography scanner technologies, 3D auto-stereoscopic displays, fiber lasers and waveguide micro lasers for applications in medical, high-tech and industrial sectors. Founded in 2004, Zecotek operates three divisional companies: Zecotek Imaging (medical, industrial and research), Zecotek Lasers (industrial and research) and Zecotek 3D (monitors for multimedia, entertainment, industrial and medical). The Company has labs located in Canada, Singapore and Russia, with affiliated R&D and production facilities in USA, China, and South Korea. Zecotek commercializes its novel, patented and patent-pending photonic technologies directly and through strategic alliances with multinational OEMs, distributors and other industry leaders. For more information, visit www.zecotek.com.
This press release may contain forward-looking statements that are based on management’s expectations, estimates, projections and assumptions. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what may have been stated.
For Additional Information Please Contact:
Zecotek Photonics Inc.
T: (604) 783-8291
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the content of this news release. If you would like to receive news from Zecotek in the future please visit the corporate website at www.zecotek.com.